A clinical-stage biotechnology company
PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology based on the Company’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology. These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, leading to the inhibition of key pathological mechanisms without altering physiological mechanisms.
PEP-010, first CP&IP-based drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is entering Phase Ia/b clinical trials for the treatment of advanced solid tumors in partnership with Institut Curie and Gustave Roussy, two leading European cancer centers.
Backed by international investors
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, Anaxago, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and by Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier, Founding Chairman of Fournier-Majoie Foundation for Innovation (FFMI).